Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Artios Launches With £25m To Study ‘PARP-esque’ DNA Damage Response Inhibitors

Executive Summary

Next generation DNA repair is the basis of new oncology-focused Artios Pharma, which has launched with a £25m series A round and a ‘PARP-esque’ discovery program.

Advertisement

Related Content

VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings
UK's Mission Banks £60m To Develop DUB Inhibitors

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC097338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel